The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...
A groundbreaking study introduces stable inhalable mRNA treatment using nanoparticles that hold up during nebulization, ...
The authors have filed a patent on this technology. Some authors are founders of oRNA Therapeutics and Moderna, biotechnology ...
Barchart on MSN1d
Moderna Stock Outlook: Is Wall Street Bullish or Bearish?With a market cap of $18 billion, Moderna is at the forefront of innovative healthcare solutions, pioneering treatments for ...
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
The Canadian Press on MSN5d
Health Canada approves Moderna's mRNA RSV vaccine, company saysHealth Canada has approved Moderna's mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and older — ...
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
Both stocks have made significant breakthroughs. Among the qualities a biotech company needs to be successful, being innovative is one of the most important. It's easy to understand why. Although ...
Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Moderna (MRNA – Research Report) today and set a price ...
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback